Alzheimer’s has long been considered irreversible, but new research challenges that assumption. Scientists discovered that severe drops in the brain’s energy supply help drive the disease—and ...

For more than a century, people have considered Alzheimer's disease (AD) an irreversible illness. Consequently, research has focused on preventing or slowing it, rather than recovery. Despite billions ...

Washington, D.C.: The Executive Board of the International Monetary Fund (IMF) has formally completed its review of the Short-Term Liquidity Line (SLL) on December 15th. The Review concluded that the ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Please provide your email address to receive an email when new articles are posted on . Patients with CLL and SLL who received pirtobrutinib had superior response than those who received ibrutinib in ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the initial promise it saw with its BTK inhibitor Jaypirca (pirtobrutinib). Just ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...